Full Text

Turn on search term navigation

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

The LAmbreTM device is a novel system designed for left atrial appendage closure (LAAC). First registries showed a high rate of device implantation success. However, few mid-term results are available. We present our 1- and 12-month follow-up results for this device. This prospective, single-center registry included consecutive patients with nonvalvular atrial fibrillation who underwent LAAC with the LAmbreTM device. Transesophageal echocardiography (TEE) was performed at 1-month follow-up. In total, 55 patients were included. The population was elderly (75 ± 9.4 years), with a high proportion of comorbidities. The mean CHA2DS2-VASc and HAS-BLED scores were 4.6 ± 1.6 and 3.9 ± 1.0, respectively. Previous history of a major bleeding event was present in 37 patients (67.3%). Procedural success was achieved in 54 patients (98.2%). Device success was achieved in 100% of patients in whom device implantation was attempted (54 patients). Major in-hospital device-related complications included mortality of one patient (1.8%) and pericardial tamponade in two patients (3.6%); the incidence of stroke was 0%. No thrombus or significant leaks (≥5 mm) were observed on 1-month TEE. At 12 months, adverse events were overall death (1.8%), transient ischemic attack/ischemic stroke (1.8%), and major bleeding events (Bleeding Academic Research Consortium (BARC) 3a and 3c; 11%). In this high-risk population, the LAmbreTM device seems to be a safe and effective option for LAAC with a remarkable mid-term performance.

Details

Title
Left Atrial Appendage Closure with a New Occluder Device: Efficacy, Safety and Mid-Term Performance
Author
Llagostera-Martín, Marc 1   VIAFID ORCID Logo  ; Cubero-Gallego, Hector 1 ; Mas-Stachurska, Aleksandra 2 ; Salvatella, Neus 1 ; Sánchez-Carpintero, Andrea 1 ; Tizon-Marcos, Helena 2   VIAFID ORCID Logo  ; Garcia-Guimaraes, Marcos 1 ; Calvo-Fernandez, Alicia 1 ; Molina, Luis 3 ; Vaquerizo, Beatriz 3   VIAFID ORCID Logo 

 Interventional Cardiology Unit, Cardiology Department, Hospital del Mar, 08003 Barcelona, Spain; [email protected] (M.L.-M.); [email protected] (H.C.-G.); [email protected] (A.M.-S.); [email protected] (N.S.); [email protected] (A.S.-C.); [email protected] (H.T.-M.); [email protected] (M.G.-G.); [email protected] (A.C.-F.); [email protected] (L.M.) 
 Interventional Cardiology Unit, Cardiology Department, Hospital del Mar, 08003 Barcelona, Spain; [email protected] (M.L.-M.); [email protected] (H.C.-G.); [email protected] (A.M.-S.); [email protected] (N.S.); [email protected] (A.S.-C.); [email protected] (H.T.-M.); [email protected] (M.G.-G.); [email protected] (A.C.-F.); [email protected] (L.M.); Heart Diseases Biomedical Research Group (GREC), Hospital del Mar Medical Investigation Institute-IMIM, 08003 Barcelona, Spain 
 Interventional Cardiology Unit, Cardiology Department, Hospital del Mar, 08003 Barcelona, Spain; [email protected] (M.L.-M.); [email protected] (H.C.-G.); [email protected] (A.M.-S.); [email protected] (N.S.); [email protected] (A.S.-C.); [email protected] (H.T.-M.); [email protected] (M.G.-G.); [email protected] (A.C.-F.); [email protected] (L.M.); Heart Diseases Biomedical Research Group (GREC), Hospital del Mar Medical Investigation Institute-IMIM, 08003 Barcelona, Spain; Medicine Department, Autonomous University of Barcelona-UAB, 08193 Barcelona, Spain 
First page
1421
Publication year
2021
Publication date
2021
Publisher
MDPI AG
e-ISSN
20770383
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2641040125
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.